Pauls Matthew 4

What Happened

• Matthew Pauls, a director of Palvella Therapeutics, Inc. (PVLA), received a grant of 6,000 derivative shares (reported as an award/acquisition) on 2026-06-29. The filing shows a reported price of $0.00 per share, so no cash was paid as part of this award.

Key Details

• Transaction date: 2026-06-29; Form 4 filed 2026-07-01 (within the typical 2-business-day reporting window).
• Award: 6,000 derivative shares (reported as Award/Acquisition, code A) at $0.00 per share; total reported cash value = $0.
• Vesting: Footnote states the options vest in 36 equal monthly installments, subject to continued service as of each vesting date.
• Shares owned after transaction: Not specified in the provided filing.
• Filing status: No late-report flag noted in the provided data.

Context

• This was a grant/award (derivative) for compensation/retention, not an open-market buy or sale. Such awards typically vest over time and do not represent an immediate purchase or sale of tradable shares.
• Because this is a compensation grant, it should be viewed as part of insider pay/retention practices rather than a direct bullish or bearish market signal.